- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04160325
Effect of the Exclusive Enteral Nutrition Combined With Azathioprine for Remission of Crohn's Diseases After Surgery
October 16, 2023 updated by: Zhu Weiming
The Effect of the Exclusive Enteral Nutrition Combined With Azathioprine in Maintaining Remission of Patients With Crohn's Diseases After Surgery
for some patients with Crohn's diseases undergoing surgery,whether exclusive enteral nutrition(EEN) could delay the disease relapse needs exploration.The trial will study whether the efficacy of postoperative EEN could help keeping remission.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
For patients with Crohn's disease(CD), whether exclusive enteral nutrition(EEN) following bowel resection and anastomosis could delay the disease recurrence remains unkown.
In this study, CD patients after surgery will be divided into two groups: one group is treated with 3 months' EEN and then turn to normal diet after 3 months; the other group is given with normal diet all through.
All patients will be adminstrated with oral azathioprine after surgery.
Then, the rates of 1 year postoperative endoscopic recurrence will be compared between groups.
Study Type
Interventional
Enrollment (Estimated)
54
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: weiming zhu
- Phone Number: +86-025-80860036
- Email: juwiming@nju.edu.cn
Study Contact Backup
- Name: ming duan
- Phone Number: +86-025-80860037
- Email: duanming1206@126.com
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210002
- Recruiting
- Department of General Surgery, Jinling hosptal,Medical School of Nanjing University
-
Contact:
- Weiming Zhu, PhD
- Phone Number: 86-25-80863736
- Email: juwiming@nju.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- CD patients who undergoing bowel resection with anastomosis
Exclusion Criteria:
- patients who had administered with immunomodulators or biological agents patients who were created stoma
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 3 months exclusive enteral nutrition plus azathioprine
patients underwent surgery in this arm will given 3 months exclusive enteral nutrition,and free diet after 3 months.
All patients will be adminsrated with oral azathioprine to preventing disease recurrence.
|
postoperative 3-month exclusive enteral nutrition after surgery and alter to normal food after 3 months
azathioprine
|
Active Comparator: normal diet plus azathioprine
patients underwent surgery in this arm will given free diet all through.
All patients will be adminsrated with oral azathioprine to preventing disease recurrence.
|
azathioprine
normal diet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the 1 year postoperative anastomotic recurrence
Time Frame: 1 year
|
the 1 year postoperative anastomotic recurrence
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2018
Primary Completion (Estimated)
October 31, 2023
Study Completion (Estimated)
October 31, 2023
Study Registration Dates
First Submitted
November 3, 2019
First Submitted That Met QC Criteria
November 12, 2019
First Posted (Actual)
November 13, 2019
Study Record Updates
Last Update Posted (Actual)
October 17, 2023
Last Update Submitted That Met QC Criteria
October 16, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Gastrointestinal Diseases
- Gastroenteritis
- Intestinal Diseases
- Inflammatory Bowel Diseases
- Crohn Disease
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Azathioprine
Other Study ID Numbers
- jinlingH201709
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Crohn Disease
-
ProgenaBiomeRecruitingCrohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's Esophagitis | Crohn's | Crohn Disease of Ileum | Crohn Ileitis | Crohn's Disease Relapse | Crohns Disease Aggravated | Crohn Disease in Remission | Crohn's Disease of PylorusUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CelltrionRecruitingBowel Disease | Inflammatory Disease | Disease CrohnNetherlands
-
Chinese University of Hong KongTerminatedCrohn Disease | Perianal Crohn DiseaseHong Kong
-
SandozCompletedCrohn´s DiseaseAustria, Germany, Poland, Spain, Sweden
-
Dr. Falk Pharma GmbHCompleted
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
Groupe Hospitalier Paris Saint JosephCompleted
-
Ferring PharmaceuticalsTerminatedCrohn´s DiseaseUnited Kingdom, United States, Germany, Belgium, Denmark, France, Sweden
-
Jinling Hospital, ChinaCompletedCrohn Disease in RemissionChina
-
Boehringer IngelheimTerminatedFibrostenotic Crohn´s DiseaseUnited States, Canada, Japan, Sweden
Clinical Trials on postoperative 3-month exclusive enteral nutrition
-
Jinling Hospital, ChinaCompletedCrohn Disease in RemissionChina
-
University of Alabama at BirminghamActive, not recruitingEnteral Feeding Intolerance | Premature; Infant, Light-for-datesUnited States
-
Children's Hospital of Fudan UniversityCompletedCrohn Disease | Enteral Nutrition | Gastrointestinal MicrobiomeChina
-
Prof. Arie LevineCompletedCrohn's DiseaseIsrael, Canada, Ireland, Spain
-
Jinling Hospital, ChinaCompleted
-
Prof. Arie LevineCompletedCrohn's DiseaseCanada, Israel
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityCompleted
-
Belal AlshaikhCompleted
-
Tel-Aviv Sourasky Medical CenterNot yet recruiting
-
NHS Greater Glasgow and ClydeUniversity of GlasgowUnknown